{"classes":[{"categories":[{"measurements":[{"comment":"Not calculable/estimable due to insufficient number of events","groupId":"OG000","lowerLimit":"26.5","upperLimit":"NA","value":"35.3"},{"comment":"Not calculable/estimable due to insufficient number of events","groupId":"OG001","lowerLimit":"27.3","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Duration of overall response (DoR) was defined as the number of days from the date of first response (CR, CRi, nPR, or PR) by either CT scan or physical exam determination to the earliest recurrence (progressive disease; PD) or death. For participants who had a PR before CR, CRi, or nPR in subsequent visits, the DoR was computed from the earliest PR. If a participant was still responding, then their data was censored at the date of their last available disease assessment. To be included in the DoR analysis, participants must have had a response per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria (CR, CRi, confirmed nPR, or confirmed PR). For participants who never experienced response, their data was not included in the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG000","title":"Main Cohort"},{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG001","title":"Safety Expansion Cohort"}],"paramType":"MEDIAN","populationDescription":"All treated participants in the Main Cohort and the Safety Expansion Cohort with a response and available data","reportingStatus":"POSTED","timeFrame":"Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up","title":"Duration of Overall Response","type":"SECONDARY","unitOfMeasure":"months"}